― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ― ― On track to provide clinical data from the 12 mg dose cohort in early Q3 2025 and the 20 mg dose cohort by the
BATON ROUGE, La., April 24, 2025 (GLOBE NEWSWIRE) — Business First Bancshares, Inc. (NASDAQ: BFST) (Business First), parent company of b1BANK, today announced its unaudited results for the quarter ended March 31, 2025. Business First reported net income available to common shareholders of $19.2 million or $0.65 per diluted common share, increases of $4.1 million
Company committed to building a robust global patent estate across its innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, March 31, 2025 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer
They tried selling the site, but after having no luck, they were approached in May 2020 by two realtors, whose names were redacted from the decision, and asked if they would consider selling it off-market. A potential buyer was then identified by the realtors’ colleague, Elyas Salimi Sarkhab. While, at the time, Sarkhab was employed
TORONTO, March 25, 2025 (GLOBE NEWSWIRE) — Firm Capital Property Trust (“FCPT” or the “Trust”) (TSX : FCD.UN) is pleased to announce that its Montreal Industrial Portfolio Joint Venture (“Montreal Industrial JV”) has entered into a binding agreement to sell a 100% interest in a single tenant, 159,470 square foot industrial facility for gross proceeds
Now With 30+ Awarded Patents, Yieldmo Continues Pursuit of Ad Tech Excellence with Transformative Solutions NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) — Yieldmo, a leading advertising platform helping brands improve digital ad experiences through creative tech and AI, has been awarded multiple patents for technology solutions impacting predictive creative and attention signal collection. With
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate for the treatment of aggressive large B-cell lymphoma (LBCL) Presented positive initial data from Phase 1 multi-center clinical trial of IMPT-314 in patients with aggressive LBCL in the 3rd line and later setting at the
SHANGHAI, March 6, 2025 /PRNewswire/ — The first annual Palladium Global Science Award competition is now live, with a total prize fund of $350,000. Scientists, startups and research groups involved in the study, analysis and development of new applications for palladium have to submit their entries until 31 July 2025. The China Precious Metals Industry
– Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially enrolled by YE25 – Petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC phase 2 trial ongoing with clinical data update planned for 1H25 – Petosemtamab
Bargain-hunting and positive earnings results allowed the stock market to post a rebound on Tuesday, but the peso fell for a second straight trading day. The currency weakened by 12 centavos to P58.15 while the benchmark Philippine Stock Exchange index (PSEi) added 101.48 points, or 1.69 percent, to end the day at 6,094.96. The broader